Substrate processing apparatus

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Brooks Automation, Inc patent solves the following problem:

The embodiments and methods described here relate to substrate processing apparatus and, particularly, the substrate processing apparatus in the chamber connected to a Cartesian arrangement.

Our analysis of this patent is as follows:

Brooks Automation, Inc’s patent US 8960099 B2 deals with Substrate processing apparatus.
A drive system for a transport apparatus includes a plurality of permanent magnet connected to transportation facilities, a large stationary windings revealed in a field at least one of the plurality of permanent magnets , a control system to empower stationary windings provide magnetic force in the transportation equipment, and an arrangement of ferromagnetic components proximate to at least one side in the transportation equipment to provide passive stretch, pitch, and roll the transportation facilities.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Microchannel gel electrophoretic separation systems and methods for preparing and using

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Sandia Corporation patent solves the following problem:

Embodiments of the present invention generally relates to gel electrophoretic ImmunoAssay, and especially to chip electrokinetic methods for performing immunoassays. These immunoassays fast (minutes) and requires very small amounts of sample (less than a few microliters). Using a microfabricated chips as a platform for immunoassays capable of integration, similar assays, automation and the development of portable devices.

Our analysis of this patent is as follows:

Sandia Corporation’s patent US 8961766 B2 deals with Microchannel gel electrophoretic separation systems and methods for preparing and using.
A micro-analytical platform for performing electrophoresis-based immunoassays developed by integrating photopolymerized cross-linked polyacrylamide gel in a microfluidic device. The microfluidic immunoassays made by gel electrophoretic separation and quantifying analyte concentration based on conventional polyacrylamide gel electrophoresis (PAGE). To have the biological activity of the protein and keep the whole immune complexes, native PAGE conditions used. Both directly (non-competitive) and competitive ImmunoAssay format shown in the microchip to identify toxins and biomarkers (cytokines, c-reactive protein) in body fluids (serum, saliva, oral fluid). Moreover, a description of the gradient gel fabrication included, in an effort to describe the methods we developed for further optimization of the chip PAGE immunoassays. The described chip-based PAGE ImmunoAssay procedure can immunoassays fast (minutes) and requires very small amounts of sample (less than a few microliters). Using a microfabricated chips as a platform capable of integration, similar assays, automation and the development of portable devices.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-CD40 targeted fusion proteins

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Baylor Research Institute patent solves the following problem:

Without limiting the scope of the invention, the background described in connection with antigen presentation.

Our analysis of this patent is as follows:

Baylor Research Institute’s patent US 8961991 B2 deals with Anti-CD40 targeted fusion proteins.
The present invention includes compositions and methods for the expression, secretion and utilization of novel compositions for use as, for example, vaccines and antigen delivery vector, the delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragment thereof, including humanized antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Immersion lithographic apparatus and device manufacturing method with a projection system having a part movable relative to another part

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Asml Netherlands B.V. patent solves the following problem:

The term of the following devices as here employed should be broadly interpreted as referring to any device that can be used to endow an incoming radiation beam with a patterned cross-section, which equals a pattern that is created in a target portion of the substrate; The term light valve can also be used in this context. Often, the pattern corresponding to a particular functional layer in a device made of target, such as an integrated circuit or other device (see below). Examples of such steps might include:

Our analysis of this patent is as follows:

Asml Netherlands B.V.’s patent US 8964163 B2 deals with Immersion lithographic apparatus and device manufacturing method with a projection system having a part movable relative to another part.
A lithographic projection apparatus is disclosed in which at least part of a space between a projection system equipment and a substrate filled with a liquid in a liquid supply system. The projection system separated into two separate physical parts. With substantially no direct connection between the two parts of the projection system, trembling prompted a first of two parts by joining forces with the liquid filling the space when the substrate moves relative liquid supply system affect substantially only the first part of the projection system and the rest of the second half.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Lithographic apparatus and device manufacturing method

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Asml Netherlands B.V. patent solves the following problem:

The present invention relates to a lithographic projection apparatus and a device manufacturing method.

Our analysis of this patent is as follows:

Asml Netherlands B.V.’s patent US 8964164 B2 deals with Lithographic apparatus and device manufacturing method.
A lithograph device, a local area of ​​the substrate surface under a projection system immersed in liquid. The length of a liquid supply system on the surface of the substrate can be varied using actuators. A control system using feedforward or feedback to control the input face length on the substrate to maintain the liquid supply system to a predetermined length on the surface of the substrate.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Biochip including conductive particle and device for detecting target antigen comprising the same

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Lg Electronics Inc. patent solves the following problem:

A point-of-care test is a rapid test examination to obtain information related to the disease by using fluids in a general human body. A range of structural measures related to building a detector launched as an attempt to obtain a low detection threshold (high performance detection).

Our analysis of this patent is as follows:

Lg Electronics Inc.’s patent US 8961883 B2 deals with Biochip including conductive particle and device for detecting target antigen comprising the same.
A biochip including the conductive particle and a device to their target antigen comprising the biochip declared. According to the present invention, a target antigen can be effectively detected using a small amount of target antigen, in which nonspecific detection signal can be reduced and an enhanced signal.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

TFPI inhibitors and methods of use

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Baxter International, Inc., , Baxter Healthcare Sa patent solves the following problem:

Hemostasis rely on complex coagulation cascade, where a series of events mediated blood clotting factors lead to the conversion of prothrombin to thrombin. Factor X (FX) activation is the center of activity there and extrinsic pathways of coagulation cascade. The extrinsic way suggested as the main activator of coagulation cascade (Mackman et al., Arterioscler. Thromb. Case. Biol., 27, 1687-1693 (2007)). Circulating Tissue Factor (TF) and activated Factor VII (FVIIa) will form the extrinsic complex, mediates activation of the dead. The coagulation cascade is amplified in no way, during subsequent activation of factor XII, XI, IX and VIII results in the formation of indigenous Fixa FVIIIa also complicated mediated activation. Activate dead promote thrombin formation, necessary for the body to fibrin and effectively reduce bleeding.

Our analysis of this patent is as follows:

Baxter International, Inc., , Baxter Healthcare Sa’s patent US 8962563 B2 deals with TFPI inhibitors and methods of use.
invention provides peptides that bind to Tissue Factor Way inhibitor (TFPI), including the TFPI-inhibitory peptide, and its composition. Peptide complexes also given. The peptide may be used to inhibit TFPI, enhance thrombin formation in a clotting factor-deficient subjects, increase in blood clot formation in a subject, treating a blood coagulation disorder in a subject, purification of TFPI, and to recognize a TFPI-sealing compound.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

High concentration antibody and protein formulations

File for Quick & Easy Patent Protection with PowerPatent.

The Genentech, Inc. patent solves the following problem:

This invention relates to highly concentrated formulation of the antibody, which is most suitable for subcutaneous administration. The invention further provides strong, very together (eg, 100 mg / ml protein) liquid formulations.

Our analysis of this patent is as follows:

Genentech, Inc.’s patent US 8961964 B2 deals with High concentration antibody and protein formulations.
The present application relates to highly concentrated antibody and protein formulations with reduced viscosity strong, relatively isotonic and low turbidity. The formulations are suitable for subcutaneous administration. The application further describes the articles making up the formulation and methods of using them to treat disorders treatable by the formulated antibody or protein.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Antibody Fc mutants with ablated effector functions

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Janssen Biotech, Inc. patent solves the following problem:

The invention relates to human IgG2 antibody constant region (Fc region) mutated so that they largely lose the capacity to specifically bind Fc receptor or activate mitogenic response by immune cells to the Fc receptor mediated cross-linking the surface of target antigens. invention also provides novel antibody into which mutated IgG2 constant regions can attach.

Our analysis of this patent is as follows:

Janssen Biotech, Inc.’s patent US 8961967 B2 deals with Antibody Fc mutants with ablated effector functions.
Antibody and other Fc-containing molecules between the Fc region to reduce binding to Fc gamma receptor and resulting activity and can be used in the treatment of various diseases and disorders.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Antibodies against ERBB3 and uses thereof

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Merrimack Pharmaceuticals, Inc. patent solves the following problem:

The erbB / HER family receptor polypeptide growth factors involved in skin growth factor (EGF) receptor (EGFR, ErbB1 / HER1), the Neu oncogene products (erbB2 / HER2), and the more recently recognized erbB3 / HER3 and erbB4 / HER4 receptor proteins (see, for example, Hynes et. al. (1994) Biochim. Biophys. Acta Pin Cancer 1198, 165-184). Each of these cells is predicted to consist of an extracellular ligand-binding domain, a membrane-spanning domain, a cytosolic protein tyrosine kinase (PTK) domain and a C-terminal domain phosphorylation ( see, for example, Kim et al., (1998) Biochem. J. 334, 189-195).

Our analysis of this patent is as follows:

Merrimack Pharmaceuticals, Inc.’s patent US 8961966 B2 deals with Antibodies against ERBB3 and uses thereof.
The present invention provides a new class of monoclonal antibody to bind erbB3 receptor and inhibits various erbB3 functions. For example, the antibody described herein can bind to erbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.